Real-World Safety Profile of Xanomeline-Trospium (Cobenfy), the First Muscarinic Agonist Antipsychotic: A Disproportionality Analysis of the FDA Adverse Event …
1. 系统已在2026-07-31 12:02:13对应助文件进行删除
2. 如有需要请重新发布求助信息
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规
DOI:
文献链接:
其他信息:
H Farquhar
Available at SSRN 6611902
papers.ssrn.com
Background: Xanomeline-trospium (Cobenfy), the first antipsychotic with a non-dopaminergic mechanism approved in over 30 years, received FDA approval for schizophrenia in September 2024. Its muscarinic M1/M4 agonist mechanism may produce a different adverse event profile compared with conventional antipsychotics, but post-marketing data have not been comprehensively evaluated with active-comparator analyses. We aimed to characterise the safety profile of xanomeline-trospium using …

